Larry Warner, MD
Psychiatry · Baton Rouge, LANPI 1851552806
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $380,250 of the $495,005 with a category attached, or 76.8%. Neurocrine Biosciences, Inc. accounts for 95.4% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $160,465, more than ten times the $474 reported in 2019. Among psychiatry clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 736 payments — averaging $672.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$472K
- Alkermes, Inc.$17K
- Otsuka America Pharmaceutical, Inc.$4K
- Orexo US, Inc.$487
- Teva Pharmaceuticals USA, Inc.$226
- Avanir Pharmaceuticals, Inc.$115
- plus $514 from 8 others
What the payments were for
- Consulting fees$25,5885%
- Speaking & faculty fees$380,25077%
- Travel & lodging$76,56015%
- Food & beverage$12,5373%
- Education$690%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 592 | $472,430 |
| Alkermes, Inc. | 33 | $16,948 |
| Otsuka America Pharmaceutical, Inc. | 19 | $4,285 |
| Orexo US, Inc. | 32 | $487 |
| Teva Pharmaceuticals USA, Inc. | 21 | $226 |
| Avanir Pharmaceuticals, Inc. | 8 | $115 |
| Lundbeck LLC | 7 | $107 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $104 |
| Neuronetics, Inc. | 2 | $98 |
| Johnson & Johnson | 5 | $80 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $67 |
| Corium, LLC | 1 | $27 |
| Shire North American Group Inc | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$463,656
- LYBALVI$64,714
- REXULTI$3,968
- ABILIFY MAINTENA$827
How this compares
$495,005 in reported general payments places this provider in the 95th percentile of 474 psychiatry providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 19 | $21,918 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 73 | $12,119 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 87 | $1,578 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 24 | $1,362 |
| Ziprasidone Hcl | 15 | $1,250 |
| Quetiapine Fumarate | 88 | $1,049 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 49 | $1,045 |
| Duloxetine Hcl | 51 | $802 |
| Bupropion XlBupropion Hcl | 41 | $544 |
| Sertraline Hcl | 73 | $461 |
| Fluoxetine Hcl | 49 | $435 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 13 | $260 |
| Benztropine Mesylate | 12 | $230 |
| Paroxetine Hcl | 11 | $210 |
| Hydroxyzine Pamoate | 40 | $189 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $80 | $21,91819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 474 psychiatry providers in Louisiana.
Other psychiatry in Baton Rouge
- Abdul KhanBaton Rouge$156K
- Donna FargasonBaton Rouge$11K
- Aniedi UdofaBaton Rouge$9K
- Sudheera RachamalluBaton Rouge$7K
- Jason BoudreauxBaton Rouge$5K
- Anupama AtluriBaton Rouge$5K
- Patrick HayesLake Charles$837K
- Maria CruseThibodaux$522K
- Gregory BrownShreveport$495K
- Arwen PodestaNew Orleans$466K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.